Now that the MANF study data has been confirmed a "big pharma" development partnership could move the share price to .50 overnight.
Noted bio-tech analyst, Jason Napadano, says that the company should be currently valued at .20/share without having attributed any value to Amarantus Diagnostics which could be generating $300,000,000 in annual revenues within three years.
The company is substantially undervalued currently.
"The Stage is Now Set for Growth: Focus on Parkinson’s and Alzheimer’s"
“We began the quarter with a strong emphasis on the Company’s lead therapeutic program: a disease-modifying treatment for Parkinson’s. As the quarter concludes we are set to announce additional animal data in that program, as well as a number of updates on other aspects of our MANF Program. Parkinson’s continues to be at the core of the Company’s plans for the future while we evaluate the value of other MANF programs, including Myocardial Infarction, Traumatic Brain Injury and Orphan diseases. We will be providing updates in regards to each of these other programs in the near future.”
“A key area of internal focus over the last quarter has been on our recently licensed LymPro Alzheimer’s Diagnostic Blood Test, which has taken on increasing importance as the role of early stage diagnostics has been further validated by the FDA’s clear guidance to pharmaceutical companies regarding the need to focus therapeutic development on early stage patients. There are a number of disease-modifying drug candidates with blockbuster potential currently in late-stage development by leading biopharmaceutical companies; LymPro would enhance those programs by providing drug developers with a better way to efficiently conduct the NDA-enabling Phase 3 clinical trials required to gain FDA approval. We are finalizing product development plans in this area."